Pyrazolo[1,5-a]pyrimidine-based inhibitors of HCV polymerase
作者:Janeta Popovici-Muller、Gerald W. Shipps、Kristin E. Rosner、Yongqi Deng、Tong Wang、Patrick J. Curran、Meredith A. Brown、M. Arshad Siddiqui、Alan B. Cooper、José Duca、Michael Cable、Viyyoor Girijavallabhan
DOI:10.1016/j.bmcl.2009.09.087
日期:2009.11
The present paper describes a novel series of HCV RNA polymerase inhibitors based on a pyrazolo[1,5-a]pyrimidine scaffold bearing hydrophobic groups and an acidic functionality. Several compounds were optimized to low nanomolar potencies in a biochemical RdRp assay. SAR trends clearly reveal a stringent preference for a cyclohexyl group as one of the hydrophobes, and improved activities for carboxylic acid derivatives. (C) 2009 Elsevier Ltd. All rights reserved.
PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS
申请人:Neogenesis Pharmaceuticals, Inc.
公开号:EP1511751B1
公开(公告)日:2008-03-19
US7196111B2
申请人:——
公开号:US7196111B2
公开(公告)日:2007-03-27
US7449488B2
申请人:——
公开号:US7449488B2
公开(公告)日:2008-11-11
[EN] PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS<br/>[FR] PYRAZOLO[1,5-A]PYRIMIDINES SERVANT D'INHIBITEURS DE PROTÉINES KINASES
申请人:SCHERING CORP
公开号:WO2007044410A1
公开(公告)日:2007-04-19
[EN] In its many embodiments, the present invention provides a novel class of pyrazolo[1 ,5-a] pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions. Formula (I). [FR] Dans ses nombreux modes de réalisation, la présente invention concerne une nouvelle classe de composés pyrazolo[1,5-a]pyrimidines servant d'inhibiteurs de protéines kinases et/ou de kinases "points de contrôle" (checkpoint kinases), des procédés de préparation de tels composés, des compositions pharmaceutiques comprenant un ou plusieurs de ces composés, des procédés de préparation de formulations pharmaceutiques comprenant un ou plusieurs de ces composés et des procédés de traitement, de prévention, d'inhibition ou d'amélioration d'une ou plusieurs maladies associées aux protéines kinases ou aux checkpoint kinases utilisant de tels composés ou de telles compositions pharmaceutiques. Formule (I).